# Linaclotide (Linzess)

> Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.

Source: https://peptides.cafe/peptide/linaclotide
Category: GC-C Agonist · Gastrointestinal
Tag: FDA-Approved · GI

## Mechanism
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.

## Research areas
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children

## Common research protocols
- Oral: 72–290 mcg orally once daily on empty stomach.

## Study summaries
- "Linaclotide phase 3 trials" — NEJM (2011): Improved abdominal pain and bowel function in IBS-C.

## Considerations
- FDA-approved.
- Contraindicated in children <2 years; diarrhea common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.